Thrombopoietin receptor agonists: ten years later

Area of Science:

• Hematology
• Pharmacology

Background:

• Immune thrombocytopenia (ITP) treatment has evolved with the introduction of thrombopoietin receptor agonists (TPO-RA).
• Eltrombopag and romiplostim, TPO-RAs, were approved for ITP in 2008 and are now used globally.

Purpose of the Study:

• To review the efficacy and safety of TPO-RAs in immune thrombocytopenia (ITP).
• To evaluate current knowledge and remaining questions regarding TPO-RA use in ITP management.

Main Methods:

• Analysis of data from six major randomized controlled trials in ITP.
• Review of prospective and retrospective studies on TPO-RA mechanism, efficacy, and toxicity.
• Evaluation of safety concerns, including myelofibrosis and venous thromboembolism.

Main Results:

• TPO-RAs demonstrate significant platelet response rates (50-90%) in ITP patients.
• These agents effectively reduce bleeding and the need for rescue medications.
• Concerns regarding myelofibrosis have largely not been confirmed, with fibrosis often reversible; however, increased risk of venous thromboembolism is noted.

Conclusions:

• TPO-RAs are effective treatments for chronic ITP refractory to other therapies.
• While generally well-tolerated, careful monitoring for venous thromboembolism is warranted.
• Further research is needed to address outstanding questions regarding TPO-RA use.